A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Ultevursen (Primary)
- Indications Retinitis pigmentosa; Usher syndromes
- Focus Therapeutic Use
- Acronyms LUNA
- 21 Nov 2024 Planned initiation date changed from 1 Dec 2024 to 9 Dec 2024.
- 21 Nov 2024 Status changed from not yet recruiting to recruiting.
- 10 Oct 2024 New trial record